Show simple item record

dc.contributor.authorBakare, Olalekan
dc.contributor.authorGokul, Arun
dc.contributor.authorKeyster, Marshall
dc.date.accessioned2021-09-01T07:20:06Z
dc.date.available2021-09-01T07:20:06Z
dc.date.issued2021
dc.identifier.citationBakare, Olalekan & Gokul, Arun & Wu, Ruomou & Niekerk, Lee-Ann & Klein, Ashwil & Keyster, Marshall. (2021). Biomedical Relevance of Novel Anticancer Peptides in the Sensitive Treatment of Cancer. Biomolecules. 11. 1120. 10.3390/biom11081120.en_US
dc.identifier.uri10.3390/biom11081120.
dc.identifier.urihttp://hdl.handle.net/10566/6584
dc.description.abstractThe global increase in cancer mortality and economic losses necessitates the cautious quest for therapeutic agents with compensatory advantages over conventional therapies. Anticancer peptides (ACPs) are a subset of host defense peptides, also known as antimicrobial peptides, which have emerged as therapeutic and diagnostic candidates due to several compensatory advantages over the non-specificity of the current treatment regimens. This review aimed to highlight the ravaging incidence of cancer, the use of ACPs in cancer treatment with their mechanisms, ACP discovery and delivery methods, and the limitations for their use. This would create awareness for identifying more ACPs with better specificity, accuracy and sensitivity towards the disease. It would also promote their efficacious utilization in biotechnology, medical sciences and molecular biology to ease the severity of the disease and enable the patients living with these conditions to develop an accommodating lifestyle.en_US
dc.language.isoenen_US
dc.publisherMDPIen_US
dc.subjectanticancer peptides; apoptosis; cancer; cytolysis; host-defense peptides; peptide deliveryen_US
dc.titleBiomedical Relevance of Novel Anticancer Peptides in the Sensitive Treatment of Canceren_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record